Report
CDMO Market for Cell and Gene Therapy
This report analyzes the Contract Development and Manufacturing Organization (CDMO) market for cell and gene therapy (CGT), a rapidly expanding segment driven by rising demand for advanced therapies. The global CGT CDMO market is projected to grow at a compound annual growth rate (CAGR) of 17.5% from 2021 to 2026, increasing from approximately USD 4.6 billion in 2021 to USD 10.2 billion by 2026. Growth is closely linked to the broader CGT market, which is expected to expand at an even faster pace due to increasing regulatory approvals and a growing pipeline of therapies. As more cell and gene therapies move through clinical development and commercialization, specialized CDMOs are playing an increasingly important role by providing manufacturing expertise, scalable production capabilities,
